LaserSight receives FDA approval for LASIK keratomileuisis study

17 Jun 2002

LaserSight, Inc., has received authorization from the U.S. Food and Drug Administration to incorporate LaserSight's automated disposible keratome into its national study regarding Laser In-Situ Keratomileosis, or LASIK. The study, conducted by CRS Clinical Research, Inc., is in its second year and includes the treatment of myopia, astigmatism, and hyperopia. Keratomes are surgical instruments used to create a thin corneal flap during refractive surgery.